Option activity is usually called unusual when a contract trades much more volume than its open interest, which can mean traders are opening new positions.

On Nov 4, 2026, Allogene Therapeutics options traded 280 contracts against 17.02K open, a volume to open interest ratio of 0.02, below its 20-day average. The table above lists the contracts with the highest ratios.

Calls made up 89.3% of Allogene Therapeutics option volume on Nov 4, 2026, a put/call ratio of 0.12, so calls outnumber puts. The ALLO option volume chart shows calls and puts by strike.

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases.